310
Participants
Start Date
March 10, 2017
Primary Completion Date
June 24, 2019
Study Completion Date
April 23, 2021
Ruxolitinib (RUX)
Ruxolitinib was provided as 5 mg tablets for oral use.
Best Available Therapy (BAT)
BAT was based on the investigator's best judgment, taking into account the manufacturer's instructions, labeling, patient's medical condition, and institutional guidelines for any dose adjustment. The BAT in this study was identified by the investigator prior to patient randomization among the following treatments currently used in this setting: anti-thymocyte globulin (ATG), extracorporeal photopheresis (ECP), mesenchymal stromal cells (MSC), low-dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), etanercept, or infliximab. No other types or combinations of BAT were permitted.
Novartis Investigative Site, Sofia
Novartis Investigative Site, Westmead
Novartis Investigative Site, Parkville
Novartis Investigative Site, Herston
Novartis Investigative Site, Murdoch
Novartis Investigative Site, Graz
Novartis Investigative Site, Torino
Novartis Investigative Site, Riyadh
Novartis Investigative Site, Berlin
Novartis Investigative Site, Berlin
Novartis Investigative Site, Genova
Novartis Investigative Site, Milan
Novartis Investigative Site, Hamburg
Novartis Investigative Site, Bergamo
Novartis Investigative Site, Besançon
Novartis Investigative Site, Brescia
Novartis Investigative Site, Madrid
Novartis Investigative Site, Madrid
Novartis Investigative Site, Málaga
Novartis Investigative Site, Hanover
Novartis Investigative Site, Toulouse
Novartis Investigative Site, Oviedo
Novartis Investigative Site, Udine
Novartis Investigative Site, Pessac
Novartis Investigative Site, Vigo
Novartis Investigative Site, Grenoble
Novartis Investigative Site, Bologna
Novartis Investigative Site, Düsseldorf
Novartis Investigative Site, Taichung
Novartis Investigative Site, Seville
Novartis Investigative Site, Istanbul
Novartis Investigative Site, Saint Priest En Jarez
Novartis Investigative Site, Essen
Novartis Investigative Site, Valencia
Novartis Investigative Site, Münster
Novartis Investigative Site, Angers
Novartis Investigative Site, Florence
Novartis Investigative Site, Vandœuvre-lès-Nancy
Novartis Investigative Site, Mainz
Novartis Investigative Site, Lille
Novartis Investigative Site, Lille
Novartis Investigative Site, Ancona
Novartis Investigative Site, Mannheim
Novartis Investigative Site, Pierre-Bénite
Novartis Investigative Site, San Giovanni Rotondo
Novartis Investigative Site, Tübingen
Novartis Investigative Site, Paris
Novartis Investigative Site, Paris
Novartis Investigative Site, Paris
Novartis Investigative Site, Paris
Novartis Investigative Site, Freiburg im Breisgau
Novartis Investigative Site, Augsburg
Novartis Investigative Site, Limoges
Novartis Investigative Site, Ulm
Novartis Investigative Site, Moscow
Novartis Investigative Site, Haifa
Novartis Investigative Site, Petah Tikva
Novartis Investigative Site, Tel Aviv
Novartis Investigative Site, Jerusalem
Novartis Investigative Site, Linz
Novartis Investigative Site, Calgary
Novartis Investigative Site, Vancouver
Novartis Investigative Site, Hamilton
Novartis Investigative Site, Ottawa
Novartis Investigative Site, Toronto
Novartis Investigative Site, Montreal
Novartis Investigative Site, Montreal
Novartis Investigative Site, Saskatoon
Novartis Investigative Site, Prague
Novartis Investigative Site, Copenhagen
Novartis Investigative Site, Nice
Novartis Investigative Site, Dresden
Novartis Investigative Site, Jena
Novartis Investigative Site, Leipzig
Novartis Investigative Site, Thessaloniki
Novartis Investigative Site, Hong Kong
Novartis Investigative Site, Izmir
Novartis Investigative Site, Roma
Novartis Investigative Site, Nagoya
Novartis Investigative Site, Fukuoka
Novartis Investigative Site, Sapporo
Novartis Investigative Site, Kobe
Novartis Investigative Site, Nishinomiya
Novartis Investigative Site, Isehara
Novartis Investigative Site, Sendai
Novartis Investigative Site, Okayama
Novartis Investigative Site, Suita
Novartis Investigative Site, Bunkyo Ku
Novartis Investigative Site, Chuo Ku
Novartis Investigative Site, Minato Ku
Novartis Investigative Site, Shinjuku-ku
Novartis Investigative Site, Osaka
Novartis Investigative Site, Utrecht
Novartis Investigative Site, Oslo
Novartis Investigative Site, Seoul
Novartis Investigative Site, Seoul
Novartis Investigative Site, Barcelona
Novartis Investigative Site, Barcelona
Novartis Investigative Site, Ankara
Novartis Investigative Site, Ankara
Novartis Investigative Site, London
Novartis Investigative Site, London
Novartis Investigative Site, Manchester
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY